Agaroid Structures with Interconnected Pores for Tissue Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing agaroid structures lack the ability to form monolithic structures with interconnected pores, which limits their applications in wound treatment, bone grafting, and drug delivery.
Innovation Solution
The development of agaroid structures with unique techniques that produce monolithic structures with interconnected pores, allowing them to absorb and release water, and optionally being chemically cross-linked, sintered, or containing pore-forming agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional agaroid structures are used, then they are simple to manufacture, but they lack interconnected pores and monolithic structure
Solution Approach 1:
The patent applies preliminary action by pre-forming a monolithic agaroid structure with controlled porosity before introducing beneficial agents. The agaroid matrix is prepared in advance with specific pore characteristics, then agents are incorporated or applied subsequently, enabling precise control over structure uniformity while maintaining manufacturing feasibility
Solution Approach 2:
The patent uses composite materials by combining agaroid with beneficial agents (pharmaceuticals, biologics, imaging agents) to create a multifunctional material system. This composite approach achieves superior structure uniformity and functionality while the manufacturing process remains adaptable to existing techniques
2Quantity of substance
If agaroid structures with interconnected pores are created, then absorption and retention capabilities are enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent directly applies porous materials by creating agaroid structures with controlled interconnected pore networks. The porosity is optimized to enhance absorption capacity for fluids and beneficial agents, while the pore size and distribution are controlled during manufacturing to balance absorption performance with structural manageability
Solution Approach 2:
The patent uses parameter changes by controlling physical and chemical parameters during agaroid formation, including gel concentration, crosslinking degree, and pore-forming agent ratios. These parameter adjustments enable tuning of absorption capacity while keeping the manufacturing process within feasible complexity limits
3Adaptability or versatility
If multiple beneficial agents are incorporated into agaroid structures, then therapeutic versatility is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent applies universality by designing a single agaroid platform that can accommodate multiple types of beneficial agents including pharmaceuticals, biologics, imaging agents, and growth factors. The universal agaroid matrix structure and incorporation methods enable diverse applications without requiring fundamentally different manufacturing approaches for each agent type
Solution Approach 2:
The patent uses local quality by enabling spatially controlled distribution of different beneficial agents within the agaroid structure. Different agents can be localized to specific regions or depths of the matrix, allowing tailored therapeutic profiles while using standardized manufacturing techniques adapted for multi-agent incorporation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The agaroid structures exhibit enhanced absorption and retention capabilities, making them suitable for wound treatment, bone grafting, and drug delivery applications, while also providing a scaffold for tissue regeneration.
Implementation Method 1
The porous nature of some of the disclosed agaroids allows them to be somewhat sponge-like, readily absorbing water when present
Implementation Method 2
releasing the water absorbed when squeezed
Data Source
AI summary
Agaroid structures in the form of an agaroid matrix, a sintered agaroid, or an agaroid mat are disclosed which may, in some embodiments, include a chemically crosslinked agaroid, a derivatized agaroid, and/or an agaroid coupled with one or more ligands. The agaroid structures may be formed by precipitation from a glycol solution, in some cases, and may be converted to be insoluble in water below 40C. In another aspect, methods of treating a condition of a mammal are disclosed, which include contacting an area of a mammalian body with a composition having an agaroid structure with or without one or more beneficial agents. In yet another aspect, the present disclosure provides methods of filling or bulking tissue in a mammalian body by implanting a converted agaroid composition into the mammalian body, which may include converted agaroid microbeads and/or converted agaroid particles.